The total number of records retrieved from this search are 15. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_659	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_660	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result96% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_661	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result92% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_662	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result92% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_663	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_664	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result88% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_665	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result94% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_666	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_667	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result91% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_668	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (antagonism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result88% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_699	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result108% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_700	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result90% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_701	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_702	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result85% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_703	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell lineWM1791c	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result92% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486